ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Liver cirrhosis

Cumulative number of liver-related clinical outcomes (variceal bleeding, ascites, spontaneous bacterial peritonitis, infection requiring hospitalization, acute kidney injury and overt hepatic encephalopathy) and TIPS (insertion or revision) with death and liver transplantation as counting and censoring events

6-months survival, The number of episodes of acute-on-chronic liver failures, Number of organ failures, Time-to-first liver-related clinical outcome, Patients’ quality of life, Time to first hospital admission (in days), Number of hospital admissions, Days spent on hospitalization (in days), Number of intensive care unit admissions, Length of intensive care unit admissions (in days), Number of large volume paracentesis, Analysis of the cost/effectiveness ratio, Health economic evaluation, Changes in serum albumin levels, Number of treatment-related adverse events, Number of treatment-related serious adverse events, Signatures associated with a poor prognosis as defined by the Microb-Predict biomarker, Incidence of refractory ascites, Incidence of variceal bleeding, Incidence of spontaneous bacterial peritonitis, Incidence of infection requiring hospitalization, Incidence of acute kidney injury >= 1B, Incidence of hepatorenal syndrome acute kidney injury, Incidence of overt hepatic encephalopathy, Incidence of liver transplantation, Incidence of TIPS insertion or revision

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Belgium, Denmark, Germany, Hungary, Netherlands, Slovakia, Spain